Jules A. Müsing, Former Senior Executive at Johnson & Johnson, Has Been Appointed Chairman of ZyVersa Therapeutics' Board of Directors
Font : A-A+
Mr. Müsing, serving on ZyVersa's Board of Directors for over 2 years, has been instrumental in evolution of the company, and diversification into the large and growing anti-inflammatory market with our novel inflammasome inhibitor targeting ASC
Post your Comments
Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer